美国不同年龄组前列腺特异性抗原筛查试验的多水平小区域估计:2018年行为危险因素监测系统
该研究基于2018年BRFSS数据(n=116,654),采用多水平logistic回归混合模型估计美国各县不同年龄组PSA筛查患病率。结果显示筛查率随年龄增长而升高:40-54岁7.7%,55-69岁27.2%,≥70岁33.7%,且南部和阿巴拉契亚地区聚集。≥70岁男性许多县估计超过40%,提示不推荐人群中的潜在过度使用。
要点
- ≥70岁男性PSA筛查率最高(33.7%),但USPSTF不推荐该人群筛查。
- 55-69岁男性筛查率为27.2%,南部各县估计较高。
- 各县筛查率差异大,南部和阿巴拉契亚地区聚集。
核心结论
- PSA筛查在≥70岁男性中最高(33.7%),而该人群不被推荐筛查。
- 所有年龄组中南部地区筛查率较高,且州内各县差异显著。
研究设计与样本
- 研究采用多水平logistic回归混合模型,使用2018年BRFSS数据(n=116,654)及其他来源,对4个年龄组(≥40、40-54、55-69、≥70岁)进行县水平患病率估计。
- 通过Spearman和Pearson相关系数评估模型基于州的估计与BRFSS直接州估计的一致性。
主要发现
- PSA筛查患病率随年龄增加:40-54岁7.7%,55-69岁27.2%,≥70岁33.7%。
- 筛查率在南部和阿巴拉契亚地区聚集,≥70岁男性许多县估计超过40%。
- 相关系数:≥40岁男性为0.94,40-54岁、55-69岁、≥70岁男性均≥0.85。
关键数值与推荐
- 2018年USPSTF推荐55-69岁男性在充分知情并表达筛查意愿后可行PSA筛查。
- USPSTF不推荐≥70岁男性进行PSA筛查。
临床怎么用
- 全科医生应关注≥70岁男性PSA筛查的潜在过度使用,尤其在高筛查率地区。
- 在55-69岁男性中,应确保筛查决策基于知情共享决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2018, the US Preventive Services Task Force (USPSTF) recommended prostate cancer screening for men aged 55 to 69 years who express a preference for being screened after being informed about and understanding prostate-specific antigen (PSA) test benefits and risks. USPSTF recommended against screening men aged ≥70 years. We aim to generate county-level prevalence estimates, masked by national and state estimates, to identify counties with high PSA screening prevalence. METHODS: We fitted multilevel logistic regression mixed models for 4 age groups (≥40, 40 to 54, 55 to 69, ≥70 years), using data from the 2018 Behavioral Risk Factor Surveillance System (BRFSS) (n = 116,654) and other sources. We evaluated consistency between our model-based state and BRFSS direct state estimates with Spearman and Pearson correlation coefficients. RESULTS: PSA screening prevalence increased with increasing age groups: 7.7% for men aged 40 to 54 years, 27.2% for men aged 55 to 69 years, and 33.7% among men age ≥70 years, and was largely clustered in the South and Appalachia. Many county estimates among men aged ≥70 years exceeded 40%, especially in the South. Correlation coefficients were 0.94 for men aged ≥40, and ≥0.85 for men aged 40 to 54 years, 55 to 69 years, and ≥70 years. CONCLUSIONS: PSA screening was highest among men ≥70 years, for whom it is not recommended, and in the South among all age groups. Screening varied substantially within states. IMPACT: In 2018, on average, more than 1 in 4 men aged 55 to 69 years and 1 in 3 men aged ≥70 years underwent PSA screening in the prior year, suggesting potential overuse among some men.
引用
- Berkowitz Z, Zhang X, Richards TB, et al. Multilevel Small Area Estimation of Prostate-Specific Antigen Screening Test in the United States by Age Group: 2018 Behavioral Risk Factor Surveillance System. J Am Board Fam Med. 2021. PMID: 34088823. doi:10.3122/jabfm.2021.03.200505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。